Trial Profile
Phase II study to investigate the use of 'DC-TC' therapy in patients with hepatocellular caricnoma (HCC).
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Eltrapuldencel-T (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbelZeta Pharma; Cellular Biomedicine Group
- 20 Apr 2015 New trial record